Question 1

What is Ublituximab?

Accepted Answer

Ublituximab is a laboratory-engineered protein known as a monoclonal antibody. It works by binding to specific proteins on the surface of certain white blood cells to help regulate the body's immune response.

By targeting these cells, the medication helps reduce the immune system's impact on the protective insulation surrounding nerves. This mechanism is intended to help manage the underlying processes of certain chronic conditions affecting the central nervous system.

Question 2

What is Ublituximab used for?

Accepted Answer

Ublituximab is used to treat relapsing forms of multiple sclerosis .

Question 3

How does Ublituximab work?

Accepted Answer

Mechanism of Action

Ublituximab belongs to a class of medications known as monoclonal antibodies. These are laboratory-made proteins designed to recognize and attach to specific targets in the body.

Targeting B-Cells

This medication specifically targets a protein called CD20 , which is found on the surface of certain white blood cells known as B-lymphocytes (B-cells). In people with relapsing forms of multiple sclerosis (MS), these B-cells are believed to play a key role in attacking the protective covering of nerves in the brain and spinal cord.

Reducing Nerve Damage

When ublituximab binds to the CD20 protein, it triggers the immune system to remove these specific B-cells from the bloodstream. By depleting these cells, the medication helps to:

Decrease the inflammatory response that leads to MS relapses.

Reduce the formation of new lesions (damaged areas) in the central nervous system.

Slow the progression of physical disability associated with the disease.

While the exact way ublituximab exerts its therapeutic effects in MS is not fully understood, it is primarily attributed to this reduction in B-cell activity.

Question 4

What are the brand names for Ublituximab?

Accepted Answer

Ublituximab is sold under the brand name Briumvi .

Question 5

What are the active ingredients in Ublituximab?

Accepted Answer

The active ingredient in Ublituximab is ublituximab .

Question 6

What are the side effects of Ublituximab?

Accepted Answer

Common side effects of Ublituximab may include:

infusion-related reactions

upper respiratory tract infection

headache

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Ublituximab?

Accepted Answer

Ublituximab belongs to the anti-CD20 monoclonal antibody drug class.

Question 8

What is the dosage of Ublituximab and how do I take it?

Accepted Answer

Administration

Ublituximab is given as an infusion into a vein by a healthcare provider in a clinical setting, such as a hospital or infusion center. Before the infusion begins, you may receive other medications, such as a corticosteroid and an antihistamine, to help prevent or reduce the severity of infusion-related reactions.

Dosing Schedule

The treatment usually follows a specific schedule:

Initial Doses: The first two infusions are typically given a short time apart to start the treatment.

Maintenance Doses: After the initial doses are completed, subsequent infusions are usually scheduled every few months.

During and after each infusion, healthcare providers will monitor you for any signs of a reaction to the medication.

Missed Doses

If you miss an appointment for an infusion, contact your healthcare provider as soon as possible to reschedule. It is important to receive your doses on time to maintain the effectiveness of the treatment. Your doctor will determine the best timing for your next dose based on when the missed dose is eventually given.

Question 9

Is Ublituximab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Ublituximab may cause harm to an unborn baby. There is limited information regarding its use in pregnant individuals, but animal studies suggest it may lead to a decrease in certain immune cells in the fetus. Healthcare providers typically perform a pregnancy test before starting this medication to ensure the patient is not pregnant.

Individuals who can become pregnant should use effective birth control during treatment and for at least 6 months after the last dose. If you become pregnant during this time, contact your healthcare provider right away.

Breastfeeding

It is currently unknown if ublituximab is present in human breast milk or if it affects milk production. Because many medications can pass into breast milk and potentially cause side effects in a nursing infant, it is important to discuss the risks and benefits with a healthcare provider. They will help determine if you should continue breastfeeding or use this medication based on your specific health needs.

Question 10

What forms and strengths does Ublituximab come in?

Accepted Answer

Ublituximab is supplied as a sterile, preservative-free solution. It is available in the following form:

Injection: A concentrated liquid solution provided in a vial for intravenous infusion.

This medication must be diluted with a compatible solution before administration. The liquid is clear to slightly opalescent and colorless to pale yellow.

Question 11

What is the FDA approval status of Ublituximab?

Accepted Answer

The U.S. Food and Drug Administration (FDA) approved ublituximab-xiiy in December 2022. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, which includes:

Clinically isolated syndrome

Relapsing-remitting multiple sclerosis

Active secondary progressive disease

Ublituximab is classified as a CD20-directed cytolytic antibody. As part of ongoing safety monitoring, the FDA tracks adverse events through the FDA Adverse Event Reporting System (FAERS). Recent regulatory evaluations have identified potential signals of serious risks, specifically serious infections, which are monitored to determine if further labeling changes or regulatory actions are necessary.

Currently, there is no Boxed Warning or Risk Evaluation and Mitigation Strategy (REMS) program required for ublituximab. However, the medication must be administered by a healthcare professional in a clinical setting equipped to manage potential infusion-related reactions. Patients are typically screened for Hepatitis B virus and quantitative serum immunoglobulins prior to starting treatment.

Question 12

What should I know about Ublituximab and cost?

Accepted Answer

Insurance and Coverage

Ublituximab is a specialty medication, and its cost is largely determined by your insurance plan's formulary. Most insurance providers require prior authorization before they will cover the treatment. This process involves your healthcare provider submitting documentation to prove the medical necessity of the drug for your condition.

Administration Costs

Because ublituximab is given as an intravenous infusion in a clinical setting, the total price includes more than just the medication. Patients may be billed for several components, including:

The cost of the drug itself.

Nursing services and clinical supervision during the infusion.

Equipment and supplies used for the intravenous administration.

Financial Assistance Programs

The manufacturer of ublituximab often provides support services to help patients navigate insurance requirements. These services may include co-pay assistance for those with commercial insurance or patient assistance programs for individuals who are uninsured or underinsured. It is recommended to speak with a specialty pharmacy or the manufacturer's patient support line to explore these options and determine specific out-of-pocket costs.

Ublituximab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?